0
0
Excessive daytime sleepiness (EDS), a pervasive condition affecting about one in three Americans, has been linked to specific blood metabolites influenced by diet and hormones, according to a landmark study published in 2025 in The Lancet eBioMedicine. The research identifies seven key molecules tied to EDS risk, offering novel insights into biological and lifestyle contributors to this often-overlooked sleep disorder and opening new avenues for treatment and prevention.
Breaking Down Excessive Daytime Sleepiness
Excessive daytime sleepiness is characterized by an overwhelming urge to sleep during the day, even in inappropriate situations such as work or social interactions. It intimately affects daily functioning and quality of life and is associated with serious health risks including cardiovascular disease, obesity, and diabetes. Despite its prevalence, EDS remains poorly understood beyond its known causes like insufficient or disrupted nighttime sleep and certain medical conditions.
Key Study Findings
The recent study, led by Dr. Tariq Faquih of Brigham and Women’s Hospital in Boston, analyzed blood samples from over 6,000 participants in large multi-ethnic cohorts including the Hispanic Community Health Study/Study of Latinos, U.K. Biobank, and others. Researchers measured 877 metabolites—small molecules produced by metabolism—correlating their levels with reports of daytime sleepiness assessed by the Epworth Sleepiness Scale.
Seven metabolites emerged as strongly associated with EDS:
-
Omega-3 and omega-6 fatty acids such as dihomo-linoleate and docosadienoate, common in Mediterranean diets, were linked with reduced daytime sleepiness.
-
Tyramine, found in aged or fermented foods, was associated with an increased risk of EDS, particularly in men.
-
Metabolites related to steroid hormones, including those involved in melatonin regulation, also influenced sleepiness levels.
These metabolites reflect both endogenous biological processes—such as hormone biosynthesis—and external dietary factors, highlighting a complex interaction between genetics, hormones, and nutrition.
Expert Perspectives
Dr. Faquih emphasized, “Our study suggests diet and genetics may play an important role in EDS. As we learn what’s happening biologically, we are beginning to understand how and why EDS occurs, the early signs that someone might have it, and what we can do to help patients.” This points toward potential personalized interventions targeting these metabolites through dietary modification or pharmacological means.
Dr. Tamar Sofer, co-corresponding author and director of Biostatistics and Bioinformatics at Beth Israel Deaconess Medical Center, noted, “We wanted to identify biomarkers that can give stronger insights into the mechanisms of excessive daytime sleepiness and help explain why some people experience persistent sleepiness even when their sleep habits seem healthy.”
Biological and Dietary Context
Omega fatty acids, especially those prominent in Mediterranean-style diets, have known anti-inflammatory and neuroprotective effects. The study’s association of these fats with lower EDS risk supports previous research connecting healthy diets to improved sleep quality and brain function.
Conversely, tyramine in fermented foods may elevate EDS risk by interacting with hormonal pathways, suggesting diet could play a role in modulating sleepiness beyond traditional sleep hygiene advice.
Steroid hormone metabolites linked to melatonin, the hormone regulating sleep-wake cycles, underline how hormonal fluctuations affect alertness and daytime drowsiness. The study found some sex-specific differences, hinting at why men and women might experience EDS differently.
Public Health Implications
Given that EDS affects about 33% of Americans and contributes to significant health risks, these findings emphasize the importance of considering diet and hormonal health in managing daytime sleepiness. They suggest prevention strategies could include dietary guidance to increase intake of omega-3 and omega-6 fatty acids through foods such as fatty fish, nuts, whole grains, and certain vegetable oils, as well as caution around consuming aged or fermented products high in tyramine.
Moreover, understanding biological markers may encourage more precise clinical assessment and personalized treatment plans rather than relying solely on symptom-based evaluation.
Limitations and Future Research
While the study robustly links metabolites to EDS risk, it utilized questionnaire data (Epworth Sleepiness Scale) rather than sleep lab testing, which may introduce subjectivity. Metabolite measurement also varies with laboratory techniques, sometimes limiting replication across cohorts. More clinical trials are needed to evaluate whether dietary changes or supplements targeting these metabolites can causally reduce daytime sleepiness.
Continued research into unidentified metabolites connected to EDS and exploration of the interplay between genetics, lifestyle, and hormones will be essential to fully unravel mechanisms and therapeutic avenues.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
